Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J. Druker

Showing results (21-30 of 278) with videos related to

Pageof 28
Sort By:
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
The Journal of Biological Chemistry|June 22, 2002
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571Amie S Corbin, Elisabeth Buchdunger, Furet Pascal, et al.
Case Reports in Oncology|January 27, 2022
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 TranscriptsBrittany M Smith, Diana Brewer, Brian J Druker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
STI571: a paradigm of new agents for cancer therapeuticsMichael J Mauro, Michael O'Dwyer, Michael C Heinrich, et al.
Experimental Hematology|July 24, 2002
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemiaPaul La Rosée, Kara Johnson, Michael E O'Dwyer, et al.
Experimental Hematology|March 18, 2006
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemiaShadmehr Demehri, Amie Corbin, Marc Loriaux, et al.
Blood|September 25, 2013
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemiaVladimir Vainstein, Christopher A Eide, Thomas O'Hare, et al.
Plos One|June 5, 2008
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activityCollin R Elsea, Daniel A Roberts, Brian J Druker, et al.
Leukemia|September 26, 2019
Revisiting NTRKs as an emerging oncogene in hematological malignanciesSunil K Joshi, Monika A Davare, Brian J Druker, et al.
Cancer Cell|February 16, 2005
AMN107: tightening the grip of imatinibThomas O'Hare, Denise K Walters, Michael W N Deininger, et al.
Pageof 28

Showing results (21-30 of 278) with videos related to

Sort By:
Pageof 28
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
The Journal of Biological Chemistry|June 22, 2002
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571Amie S Corbin, Elisabeth Buchdunger, Furet Pascal, et al.
Case Reports in Oncology|January 27, 2022
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 TranscriptsBrittany M Smith, Diana Brewer, Brian J Druker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
STI571: a paradigm of new agents for cancer therapeuticsMichael J Mauro, Michael O'Dwyer, Michael C Heinrich, et al.
Experimental Hematology|July 24, 2002
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemiaPaul La Rosée, Kara Johnson, Michael E O'Dwyer, et al.
Experimental Hematology|March 18, 2006
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemiaShadmehr Demehri, Amie Corbin, Marc Loriaux, et al.
Blood|September 25, 2013
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemiaVladimir Vainstein, Christopher A Eide, Thomas O'Hare, et al.
Plos One|June 5, 2008
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activityCollin R Elsea, Daniel A Roberts, Brian J Druker, et al.
Leukemia|September 26, 2019
Revisiting NTRKs as an emerging oncogene in hematological malignanciesSunil K Joshi, Monika A Davare, Brian J Druker, et al.
Cancer Cell|February 16, 2005
AMN107: tightening the grip of imatinibThomas O'Hare, Denise K Walters, Michael W N Deininger, et al.
Pageof 28